File size: 4,508 Bytes
733f0d1 |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 |
{
"architectures": [
"BertForSequenceClassification"
],
"attention_probs_dropout_prob": 0.1,
"classifier_dropout": null,
"dtype": "float32",
"hidden_act": "gelu",
"hidden_dropout_prob": 0.1,
"hidden_size": 768,
"id2label": {
"0": "Benign; No actionable therapy. [COSMIC]",
"1": "Benign; No actionable therapy. [ClinVar]",
"2": "Benign; No actionable therapy. [OncoKB]",
"3": "Founder mutation; Genetic counseling required. [COSMIC]",
"4": "Founder mutation; Genetic counseling required. [ClinVar]",
"5": "Founder mutation; Genetic counseling required. [OncoKB]",
"6": "Likely oncogenic; Chemo to moderate extent. [COSMIC]",
"7": "Likely oncogenic; Chemo to moderate extent. [ClinVar]",
"8": "Likely oncogenic; Chemo to moderate extent. [OncoKB]",
"9": "Likely pathogenic; PARP inhibitors recommended. [COSMIC]",
"10": "Likely pathogenic; PARP inhibitors recommended. [ClinVar]",
"11": "Likely pathogenic; PARP inhibitors recommended. [OncoKB]",
"12": "Oncogenic; TKI therapy (osimertinib). [COSMIC]",
"13": "Oncogenic; TKI therapy (osimertinib). [ClinVar]",
"14": "Oncogenic; TKI therapy (osimertinib). [OncoKB]",
"15": "Pathogenic; Immunotherapy (pembrolizumab) advised. [COSMIC]",
"16": "Pathogenic; Immunotherapy (pembrolizumab) advised. [ClinVar]",
"17": "Pathogenic; Immunotherapy (pembrolizumab) advised. [OncoKB]",
"18": "Pathogenic; Level 1 evidence for olaparib. [COSMIC]",
"19": "Pathogenic; Level 1 evidence for olaparib. [ClinVar]",
"20": "Pathogenic; Level 1 evidence for olaparib. [OncoKB]",
"21": "Resistance mutation; Switch to alternative TKI. [COSMIC]",
"22": "Resistance mutation; Switch to alternative TKI. [ClinVar]",
"23": "Resistance mutation; Switch to alternative TKI. [OncoKB]",
"24": "Truncating variant; Radiation not advised. [COSMIC]",
"25": "Truncating variant; Radiation not advised. [ClinVar]",
"26": "Truncating variant; Radiation not advised. [OncoKB]",
"27": "VUS; Monitor and consider trials. [COSMIC]",
"28": "VUS; Monitor and consider trials. [ClinVar]",
"29": "VUS; Monitor and consider trials. [OncoKB]"
},
"initializer_range": 0.02,
"intermediate_size": 3072,
"label2id": {
"Benign; No actionable therapy. [COSMIC]": 0,
"Benign; No actionable therapy. [ClinVar]": 1,
"Benign; No actionable therapy. [OncoKB]": 2,
"Founder mutation; Genetic counseling required. [COSMIC]": 3,
"Founder mutation; Genetic counseling required. [ClinVar]": 4,
"Founder mutation; Genetic counseling required. [OncoKB]": 5,
"Likely oncogenic; Chemo to moderate extent. [COSMIC]": 6,
"Likely oncogenic; Chemo to moderate extent. [ClinVar]": 7,
"Likely oncogenic; Chemo to moderate extent. [OncoKB]": 8,
"Likely pathogenic; PARP inhibitors recommended. [COSMIC]": 9,
"Likely pathogenic; PARP inhibitors recommended. [ClinVar]": 10,
"Likely pathogenic; PARP inhibitors recommended. [OncoKB]": 11,
"Oncogenic; TKI therapy (osimertinib). [COSMIC]": 12,
"Oncogenic; TKI therapy (osimertinib). [ClinVar]": 13,
"Oncogenic; TKI therapy (osimertinib). [OncoKB]": 14,
"Pathogenic; Immunotherapy (pembrolizumab) advised. [COSMIC]": 15,
"Pathogenic; Immunotherapy (pembrolizumab) advised. [ClinVar]": 16,
"Pathogenic; Immunotherapy (pembrolizumab) advised. [OncoKB]": 17,
"Pathogenic; Level 1 evidence for olaparib. [COSMIC]": 18,
"Pathogenic; Level 1 evidence for olaparib. [ClinVar]": 19,
"Pathogenic; Level 1 evidence for olaparib. [OncoKB]": 20,
"Resistance mutation; Switch to alternative TKI. [COSMIC]": 21,
"Resistance mutation; Switch to alternative TKI. [ClinVar]": 22,
"Resistance mutation; Switch to alternative TKI. [OncoKB]": 23,
"Truncating variant; Radiation not advised. [COSMIC]": 24,
"Truncating variant; Radiation not advised. [ClinVar]": 25,
"Truncating variant; Radiation not advised. [OncoKB]": 26,
"VUS; Monitor and consider trials. [COSMIC]": 27,
"VUS; Monitor and consider trials. [ClinVar]": 28,
"VUS; Monitor and consider trials. [OncoKB]": 29
},
"layer_norm_eps": 1e-12,
"max_position_embeddings": 512,
"model_type": "bert",
"num_attention_heads": 12,
"num_hidden_layers": 12,
"pad_token_id": 0,
"position_embedding_type": "absolute",
"problem_type": "single_label_classification",
"transformers_version": "4.57.1",
"type_vocab_size": 2,
"use_cache": true,
"vocab_size": 28996
}
|